split-banner-image

ANZ 7802

Closed

ANZ 7802

BCT Study Chair:

John Forbes

Phase III trial to evaluate hormone therapy (tamoxifen) versus cytotoxic chemotherapy (adriamycin plus cyclophosphamide) versus hormone therapy plus cytotoxic chemotherapy as first line therapy in postmenopausal patients with advanced breast cancer.

international

0

INTERNATIONAL

Total number of trial

participants internationally

australia & new zealand

339

AUSTRALIA & NEW ZEALAND

Total number of trial participants

in Australia and New Zealand

institutions

14

INSTITUTIONS

Total number of participating institutions

in Australia and New Zealand

ANZ 7802 PUBLICATIONS

2002

Tamoxifen and advanced breast cancer: an overview. In: Miller WR, Ingle JN, eds. Endocrine therapy in breast cancer

Forbes JF. New York: Dekker Inc 2002; Ch 217-31,

1991

Clinical trials in breast cancer in Australia and New Zealand. In: Olweny CLM, ed. Cancer: changing concepts in management.

Coates AS, Forbes JF. Sydney: Australasian Medical Publishing Co 1991; 31-35,

1990

Clinical trials in breast cancer in Australia and New Zealand.

Coates AS, Forbes JF. Med J Aust 1990; 152601-606, Journal

1986

A randomised trial of sequential antioestrogen/cytotoxic chemotherapy vs sequential cytotoxic chemotherapy/anti-oestrogen therapy, vs combined modality therapy in 339 patients with advanced breast cancer.

Australian New Zealand Breast Cancer Trials Group, Clin Onc Soc of Aust. Reviews on Endocrine-related Cancer. 1986; 18(Suppl.):43-50, Journal

A randomised trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination.

Australian New Zealand Breast Cancer Trials Group (writing committee Coates AS, Simpson J, Forbes JF). J Clin Oncol 1986; 4(2):186-193, Journal

1982

Breast cancer: advanced disease. In: Barr Saunders B, ed.

Forbes JF. Clinics in Oncology 1982; (1):149-175,

LOAD MORE

Institutions